Yerlika is a Turkish developer and manufacturer of biotechnological drugs, supported by GMP-compliant manufacturing capabilities and extensive industry know-how. The Company aims to position itself as a regional R&D and clinical development hub in the midterm, advancing treatments across oncology, hemostatic disorders, rheumatology, osteoporosis, infertility, and hemoglobinuria.

Ziraat Portföy Element Özel GSYF acquired a majority stake in Yerlika.